Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients
Título
Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients
Autor
Giorgio Zauli, Veronica Tisato, Paola Secchiero
Fecha
2020
Materia
covid-19, antiviral activity, SARS-CoV-2, p53, MDM2, idasanutlin
Identificador
10.3389/fphar.2020.01156
Fuente
Epidemiology and Health
Editor
Korean Society of Epidemiology
Cobertura
Therapeutics. Pharmacology
Archivos
Colección
Citación
Giorgio Zauli, Veronica Tisato, Paola Secchiero, “Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients,” SOCICT Open, consulta 27 de julio de 2026, https://www.socictopen.socict.org/items/show/4525.
Position: 15466 (29 views)